학술논문
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study (vol 7, pg 6266, 2023)
Document Type
Journal
Source
Subject
Language
English
ISSN
24739537